Paragon 28 Adds Second Mobile Medical Education Lab Significantly Expanding Upon Wildly Successful Foot and Ankle Surgeon Training Program
2023年11月14日 - 6:05AM
ビジネスワイヤ(英語)
Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition
of a second trailer to its nationwide mobile lab training program
making it even more convenient for the company to facilitate
on-site surgeon training and education. Paragon 28’s new mobile lab
is housed in a 40 foot tractor-trailer which includes a
state-of-the-art, 5 station, cadaveric training facility
accommodating up to 25 surgeons. The mobile lab will host over 70
training sessions in approximately 65 US cities during quarter four
of 2023. The mobile lab program kicked off in July of 2022 and has
been an incredible success for Paragon 28, allowing the company to
efficiently train over 350 surgeons.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231113417213/en/
Paragon 28 Mobile Training Lab (Graphic:
Business Wire)
“We are very excited to add a second lab to our mobile education
program and increase our ability to bring education directly to
surgeons. The mobile lab program has allowed Paragon 28 to find the
most effective venue for medical education to support our growing
product portfolio and surgeon customers,” said Albert DaCosta, CEO
and Co-Founder of Paragon 28. “The mobile lab program has proven to
be a versatile option to showcase P28’s broad and innovative
product portfolio which includes new solutions in the growing
forefoot, HAV, and hindfoot market segments.”
To learn more about the Paragon 28 Surgeon Mobile Lab, please
visit the following site: Paragon 28 Mobile Lab
About Paragon 28, Inc.
Based in Englewood, CO., Paragon 28, is a leading medical device
company exclusively focused on the foot and ankle orthopedic market
and is dedicated to improving patient lives. From the onset,
Paragon 28® has provided innovative orthopedic solutions,
procedural approaches and instrumentation that cover a wide range
of foot and ankle ailments including fracture fixation, hallux
valgus (bunions), hammertoe, ankle, progressive collapsing foot
deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The
company designs products with both the patient and surgeon in mind,
with the goal of improving outcomes, reducing ailment recurrence
and complication rates, and making the procedures simpler,
consistent, and reproducible.
Forward Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to: Paragon 28’s potential to shape a better future
for foot and ankle patients. You are cautioned not to place undue
reliance on these forward-looking statements. Forward-looking
statements are only predictions based on our current expectations,
estimates, and assumptions, valid only as of the date they are
made, and subject to risks and uncertainties, some of which we are
not currently aware. Forward‐looking statements should not be read
as a guarantee of future performance or results and may not
necessarily be accurate indications of the times at, or by, which
such performance or results will be achieved. These forward‐looking
statements are based on Paragon 28’s current expectations and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward‐looking statements as a result of these
risks and uncertainties. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Paragon 28’s business in general, see Paragon 28’s
current and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2022 and its Quarterly Reports on Form
10-Q, as updated periodically with its other filings with the SEC.
These forward-looking statements are made as of the date of this
press release, and Paragon 28 assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231113417213/en/
Investor Contact
Matthew Brinckman Senior Vice President, Strategy and Investor
Relations Phone: (720) 912-1332 mbrinckman@paragon28.com
Paragon 28 (NYSE:FNA)
過去 株価チャート
から 4 2024 まで 5 2024
Paragon 28 (NYSE:FNA)
過去 株価チャート
から 5 2023 まで 5 2024